产品说明书

Sultiame

Print
Chemical Structure| 61-56-3 同义名 : Sulthiame
CAS号 : 61-56-3
货号 : A637802
分子式 : C10H14N2O4S2
纯度 : 99%+
分子量 : 290.359
MDL号 : MFCD00865304
存储条件:

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(172.2 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Sultiame is a carbonic anhydrase (CA) inhibitor, widely used as an antiepileptic drug[2]. CA inhibitors (CAIs) such as acetazolamide, methazolamide, topiramate, zonisamide, and sulthiame (Sultiame) can reduce seizures through perturbation of the CO(2) equilibrium and/or the inhibition of ion channels[3]. Drugs inhibiting metabolism include antibiotic macrolides, chloramphenicol, isoniazide, some sulphonamides, propoxyphene, cimetidine, valproic acid and sulthiame. Anti-epileptic drugs can induce hepatic microsomal enzymes and, therefore, may increase metabolism of corticosteroids, oral contraceptives, oral anticoagulants, cardiovascular agents, antibiotics, chemotherapeutic agents, psychotropic drugs and non-opiate analgesics, thereby reducing their efficacy[4]. The high tolerability, efficacy, convenience of use and low cost suggest that sulthiame should become a first line drug in the benign partial epilepsies of childhood and juvenile myoclonic epilepsy. It also has a role as add-on treatment in other partial and myoclonic epilepsies[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03400189 Epilepsy Phase 1 Active, not recruiting August 30, 2018 Switzerland ... 展开 >> Division of Clinical Pharmacology Lausanne, Vaud, Switzerland, 1011 收起 <<
NCT00471744 Epilepsy, Rolandic Phase 3 Terminated(low patient number ... 展开 >>after 2 years recruiting) 收起 << - Germany ... 展开 >> Dr. von Haunersches Kinderspital München, Germany, 81371 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.44mL

0.69mL

0.34mL

17.22mL

3.44mL

1.72mL

34.44mL

6.89mL

3.44mL

参考文献

[2]Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472

[3]Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):717-24

[4]Pisani F, Perucca E, Di Perri R. Clinically relevant anti-epileptic drug interactions. J Int Med Res. 1990 Jan-Feb;18(1):1-15

[5]Ben-Zeev B, Watemberg N, Lerman P, Barash I, Brand N, Lerman-Sagie T. Sulthiame in childhood epilepsy. Pediatr Int. 2004 Oct;46(5):521-4